Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial by Sanoff, Hanna K. et al.
Racial Differences in Advanced Colorectal Cancer Outcomes
and Pharmacogenetics: A Subgroup Analysis of a Large
Randomized Clinical Trial
Hanna K. Sanoff, Daniel J. Sargent, Erin M. Green, Howard L. McLeod, and Richard M. Goldberg
From the Department of Medicine, Divi-
sion of Hematology/Oncology; the
Lineberger Comprehensive Cancer
Center; and the University of North
Carolina Institute for Pharmacogenom-
ics and Individualized Therapy, Univer-
sity of North Carolina, Chapel Hill, NC;
and Division of Biomedical Statistics
and Informatics, Mayo Clinic, Roches-
ter, MN.
Submitted January 14, 2009; accepted
March 17, 2009; published online
ahead of print at www.jco.org on July
27, 2009.
Supported by National Institutes of
Health Grants No. CA25224, CA32102,
CA38926, CA21115, CA77202, and KL2
RR025746 (H.K.S.); Pfizer Oncology;
and sanofi-aventis.
Presented in part at the 42nd Annual
Meeting of the American Society of
Clinical Oncology, June 2-6, 2006,
Atlanta, GA.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Corresponding author: Richard
Goldberg, MD, University of North
Carolina Hematology-Oncology, CB
7305, 3rd Floor, Physician’s Office
Bldg, 170 Manning Dr, Chapel Hill, NC
27599-7305; e-mail: goldberg@med
.unc.edu.
The Appendix is included in the
full-text version of this article,
available online at www.jco.org.
It is not included in the PDF version
(via Adobe® Reader®).




A B S T R A C T
Purpose
Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on
comparative response to chemotherapy. A subgroup analysis of a multisite National Cancer
Institute–sponsored trial (N9741) was performed comparing outcomes of black and white patients
with metastatic CRC receiving uniform treatment.
Patients and Methods
Adverse events (AEs), response rate (RR), time to progression (TTP), overall survival (OS), and
dose-intensity were examined as a function of self-reported race in 1,412 patients treated with
irinotecan/fluorouracil, fluorouracil/oxaliplatin, or irinotecan/oxaliplatin. Pharmacogenetic analysis
was performed on 486 patients with blood available for germline DNA analysis.
Results
OS was 1.5 months shorter and TTP was 0.6 months shorter in black than white patients (OS:
hazard ratio [HR]  1.13; 95% CI, 0.90 to 1.42; TTP: HR  0.91, 95% CI, 0.73 to 1.13); neither
difference was statistically significant. RR was significantly higher in whites (41%) than blacks
(28%; P  .008). Grade 3 or greater AEs were also higher in whites (48%) than blacks (34%;
P  .004). These relationships were maintained in multivariate models adjusting for arm, age, sex,
and performance status. There was no difference in dose-intensity of delivered therapy. Significant
racial differences in prevalence of pharmacogenetic variants were observed, although small
sample size precluded investigating the relationship between treatment, race, and genotype.
Conclusion
OS and TTP are similar in black and white patients treated per protocol with standardized therapy
for metastatic CRC. However, RR and AEs vary considerably by race. The marked racial
differences in relevant pharmacogenetics, a potential explanation for differing RR and AEs, are
worthy of future study.
J Clin Oncol 27:4109-4115. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Racial disparities in outcome are well described in
cancer. Compared with white patients, minority
groups are more likely to be diagnosed with and die
from cancer in the United States.1 Blacks have a
higher incidence of colorectal cancer (CRC), are
more likely to present with advanced disease, and,
stage for stage, are more likely to die from their
disease.2-5 Recent data indicate that this gap between
black and white patients is growing because the in-
cidence and mortality of CRC are decreasing faster
in whites than blacks.3,4
The reasons underlying racial/ethnic dispari-
ties in CRC are likely multifactorial. Societal factors
influence survival because people of lower socio-
economic status are less likely to have access to
regular care, screening, and cancer treatment.1,2,6-8
Racial differences in CRC biology—blacks are more
likely to present at a younger age, with right-
sided,9,10 low- to moderate-grade tumors9—might
also mediate outcome differences, just as the pre-
ponderance of basal-like breast cancer in young
black women explains some of their poorer overall
survival (OS) when diagnosed with breast cancer.11
Finally, interpatient differences in drug efficacy and
tolerability are mediated, at least in part, by inherited
differences in drug metabolism (pharmacogenet-
ics). Race may be a proxy for pharmacogenetic dif-
ferences because toxicities or response-modifying
genotypes may occur at different frequencies among
races.12 However, there is little comparative data
regarding the response and toxicity of chemothera-
py regimens among different racial groups.
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Given that there are marked differences in outcomes between
self-described blacks and whites in population-based studies, we
thought it important to compare outcomes of these groups in a trial
setting where factors potentially related to cancer outcome, such as
access and treatment, are uniform. Although race and ethnicity are
partially societal constructs rather than biologic groupings, particu-
larly in the United States where white genetic admixture into groups of
African descent may be as high as 20%, self-reported race may be as
good a marker of genetic ancestry as genetic clustering.13-15
Thus, we explored the hypothesis that biologic differences exist
between black and white patients with regard to chemotherapy effi-
cacy by performing a subgroup analysis by self-reported race in pa-
tients treated on North Central Cancer Treatment Group trial N9741,
a randomized controlled trial funded by the National Cancer Institute
of bolus irinotecan/fluorouracil (FU)/leucovorin (LV) (IFL) versus
oxaliplatin/infusional FU/LV (FOLFOX) and bolus irinotecan and
oxaliplatin (IROX).16 We also explored the association between race
and common genetic variants of irinotecan, oxaliplatin, and FU me-
tabolizing enzymes to see if racial differences in variant distribution
might account for differences in clinical outcomes.
PATIENTS AND METHODS
Patients
Patients were treated with IFL, FOLFOX, or IROX as first-line treatment
of metastatic CRC.16 Patients with untreated metastatic CRC were enrolled
through one of the following five National Cancer Institute–sponsored coop-
erative groups (detailed eligibility criteria are available elsewhere16): North
Central Cancer Treatment Group, Cancer and Leukemia Group B, Eastern
Cooperative Oncology Group, Southwest Oncology Group, and National
Cancer Institute of Canada Clinical Trials Group. All patients signed informed
consent. The protocol was approved by the institutional review board of each
participating site.
Treatment and Study Measures
Patients were randomly assigned via a dynamic allocation to ensure
assignment was balanced for performance status (PS), prior adjuvant chemo-
therapy, prior immunotherapy, age, and randomizing location. Race was not a
stratification factor. Treatment, which is described in detail elsewhere,16 con-
sisted of IFL, FOLFOX4 (oxaliplatin, LV, and bolus then continuous-infusion
FU), or IROX administered until time of disease progression, unmanageable
toxic effects, or withdrawal of consent.
The primary objective of N9741 was to compare time to progression
(TTP) in the control arm (IFL) to TTP in the experimental arms (FOLFOX
and IROX). Secondary end points included OS, response rate (RR), and
adverse events (AEs). TTP was calculated from study entry to disease progres-
sion. Deaths occurring within 30 days of treatment discontinuation were
considered progression. OS was calculated from enrollment to death or last
contact. Patients who died or were lost to follow-up were assumed to have
experienced progression at the time they were last documented as being
progression free unless contradictory data were available. Response was clas-
sified according to the following: complete response, disappearance of all
disease and no new lesions; partial response,  50% reduction in the sum of
the products of the longest perpendicular diameters of all measurable lesions;
and progression,  25% increase in the size of measurable tumor or any new
disease. Dose-intensity was calculated as protocol-specified dose compared
with actual delivered dose at cycles 1, 3, 6, and 12. The self-reported race (white
or black) of each participant was recorded at the time of random assignment.
Pharmacogenetic Testing
A total of 520 patients consented to have their blood drawn for pharma-
cogenetic testing, 486 of whom characterized themselves as black or white and
were included in the analysis. Evaluation of 34 single nucleotide polymor-
phisms, insertion/deletion, or repeat variants in enzymes associated with FU,
irinotecan, or oxaliplatin metabolism was performed using pyrosequencing
technology, as previously reported.17
Statistical Analysis
The objectives of this secondary analysis of N9741 data were to investi-
gate the association between race and clinically relevant outcomes and to
investigate the association between genotype and race. Because the number of
nonwhite, nonblack minority patients was small (n  94, 6.2%), the analysis
compared outcomes between black and white patients only.
Univariate associations between race and OS; TTP; RR; dose-intensity at
cycles 1, 3, 6, and 12; and commonly occurring AEs were performed using 2
tests for RR and AEs and log-rank tests for the time-to-event variables of TTP
and OS. White patients serve as the reference groups for all hazard ratios (HRs)
and odds ratios (ORs). Comparisons were made across all patients and within
each treatment arm. Multivariate logistic regression and Cox proportional
hazards model were used to further investigate these associations, adjusting for
treatment arm, age, sex, and baseline PS. Race-treatment interaction terms
were included in the models, with significance testing by the likelihood ratio
test. All HRs presented are based on the multivariate models.
Associations between race and genotype were tested using 2 tests. The
small number of black patients with pharmacogenetic data (n  36) precluded
modeling the relationship between race, toxicity, and genotype. All statistical
tests are two-sided, with P  .05 denoting statistical significance.
RESULTS
Of the 1,414 patients included in the analysis, 1,297 (92%) were
white, and 117 (8%) were black. Baseline characteristics were sim-
ilar across races, although black patients were slightly younger than
whites (Table 1).
Treatment Efficacy
Across all treatment arms, OS time was slightly shorter in blacks
than whites, with a median OS of 16.3 months (95% CI, 13.3 to 18.5




PNo. % No. %





Male 66 57 793 61
Female 50 43 503 39
Treatment arm .52
IFL 39 34 371 29
FOLFOX 50 43 590 46
IROX 27 23 335 26
Baseline PS .42
0-1 109 94 1,237 96
2 7 6 57 4
Prior adjuvant therapy .06
Yes 24 21 185 14
No 92 79 1,109 86
Disease status .25
Measurable 103 89 1,098 85
Assessable 13 11 196 15
Abbreviations: IFL, irinotecan/fluorouracil/leucovorin; FOLFOX, oxaliplatin/
fluorouracil/leucovorin; IROX, irinotecan/oxaliplatin; PS, performance status.
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months) for black patients and 17.8 months (95% CI, 16.9 to 18.7
months) for white patients (HR  1.13; 95% CI, 0.90 to 1.42; Fig 1;
Table 2). In patients treated with IFL, OS for black patients was
reduced compared with white patients (15.2 months for whites v 12.2
months for blacks; HR  1.54; 95% CI, 1.08 to 2.21; P  .02).
Differences in OS between white and black patients treated with IROX
(5.3 months) and FOLFOX (2.5 months) were not statistically signif-
icant. Median TTP was similar when pooling across all treatment
arms, with a median TTP of 7.4 months (95% CI, 6.5 to 9.7 months) in
black patients and 8.0 months (95% CI, 7.4 to 8.3 months) in white
patients (HR  0.91; 95% CI, 0.73 to 1.13).
By interaction testing, there was suggestive evidence that the
effect of treatment arm on OS varied by race (Tables 2 and 3). Com-
pared with IFL, the survival benefit of IROX was greater in blacks (HR
for death  0.43 comparing IROX with IFL) than whites (HR for
death  0.90; interaction P  .007). Compared with FOLFOX, IROX
was superior to FOLFOX in blacks (HR for death  0.72 in favor of
IROX), and FOLFOX was superior to IROX in whites (HR for
death  1.31 in favor of FOLFOX; interaction P  .027). However,
TTP was longer for FOLFOX compared with IFL or IROX in all
patients regardless of race, casting doubt on the clinical relevance of
nominally statistically significant interactions for OS.
RR was lower for black patients (28%) than whites (41%), re-
gardless of treatment arm (P  .008). This difference was most pro-
nounced among FOLFOX-treated patients (28.6% black, 48% white;
P  .008). In a multivariate logistic regression model for tumor re-
sponse adjusting for age, sex, PS, and treatment arm, black patients
were significantly less likely to respond to treatment than white pa-
tients (OR  0.56; 95% CI, 0.37 to 0.86).
The rate of resection after initiation of chemotherapy did not
differ by race (1.7% in blacks v 2.3% in whites; P  1.0); receipt of
second-line chemotherapy all did not differ by race (71% in blacks v
73% in whites; P  .55). Among those initially treated with FOLFOX,
more white patients (60%) received second-line irinotecan than did
black patients (42.5%; P  .017). Among those initially treated with
IFL, there was no difference in receipt of second-line FOLFOX (33%
of blacks v 38% of whites; P  .54).
AEs
The rate of severe AEs was lower in black patients, with 34% of
blacks and 48% of whites experiencing a grade 3 or higher AE
(P  .004; adjusted OR  1.73; 95% CI, 1.2 to 2.6; Table 4). This
difference was largely a result of a higher rate of grade 3 diarrhea in
white patients (5% black v 17% white; P  .001). The increased rate of
A
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Fig 1. Kaplan-Meier plots of time to progression (TTP) and overall (OS) survival for (A) all patients and by arm: (B) irinotecan, fluorouracil, and leucovorin; (C) oxaliplatin,
fluorouracil, and leucovorin; and (D) irinotecan and oxaliplatin.
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diarrhea in whites was present across all treatment arms; however, it
was most profound in the two irinotecan-containing arms (IFL:
OR  3.6; 95% CI, 1.1 to 11.9; IROX: OR  3.6; 95% CI, 0.8 to 15.6).
There were no important differences in the rates of grade 4 neutrope-
nia, grade 3 paresthesias, or vomiting between white and black pa-
tients. Despite differences in the rates of severe AEs, there was no
meaningful difference in the dose delivered at cycles 1, 3, 6, and 12 by
race for any treatment arm (Appendix Tables A1 to A4, online only).
Pharmacogenetics
A pharmacogenetic analysis was performed in 486 patients
(black: n  36, 7%). Baseline characteristics of these patients did not
differ from the entire study population. Multiple highly significant
associations between genotype and race were observed (Table 5).
The frequencies of genetic variants in four genes related to irino-
tecan metabolism (ABCB1, CYP3A4, CYP3A5, and UGT1A1) were
significantly associated with race. In particular, the homozygous
UGT1A1*28 genotype (also called 7/7), which has been associated
with higher risk of grade 3 to 4 neutropenia,18 was more common in
blacks than whites (14% v 9%, respectively). Toxicity or efficacy vari-
ants for FU, including DPYD*2A and TYMS TSER, were not different
in frequency between black and white patients.
DISCUSSION
In this analysis of similarly staged black and white patients treated with
uniform chemotherapy and clinical follow-up, we found no meaning-
ful differences in OS or TTP between races. A statistically significant
3-month shorter survival in black patients treated with IFL was ob-
served; however, this difference was not present for the current stan-
dard of care regimen, FOLFOX. Compared with white patients,
however, black patients treated on N9741 were considerably less likely
to have an objective tumor response and less likely to have severe AEs
from chemotherapy. We identified a number of highly significant
associations between race and genotype of drug-metabolizing en-
zymes. Although these findings are provocative, our small sample size
Table 2. RR, TTP, and OS Comparisons by Race Within Treatment Arm
Treatment Arm and Race
OS TTP RR
Median (months) HR 95% CI P Median (months) HR 95% CI P % OR 95% CI P
Overall 1.13 0.90 to 1.42 .28 0.91 0.73 to 1.13 .38 0.56 0.37 to 0.86 .008
Black 16.3 7.4 28.3
White 17.8 8.0 40.9
IFL 1.54 1.08 to 2.21 .02 1.33 0.94 to 1.89 .11 0.80 0.38 to 1.68 .56
Black 12.2 5.5 28.2
White 15.2 6.8 32.8
FOLFOX 1.26 0.87 to 1.83 .23 0.80 0.57 to 1.14 .21 0.42 0.22 to 0.80 .008
Black 16.6 11.0 28.6
White 19.1 9.2 48.0
IROX 0.70 0.43 to 1.14 .15 0.73 0.46 to 1.18 .20 0.63 0.25 to 1.56 .31
Black 22.1 7.3 28.0
White 16.8 6.9 37.5
Abbreviations: RR, response rate; TTP, time to progression; OS, overall survival; HR, hazard ratio; OR, odds ratio; IFL, irinotecan, fluorouracil, and leucovorin; FOLFOX,
oxaliplatin, fluorouracil, and leucovorin; IROX, irinotecan and oxaliplatin.
HR and OR both compared blacks with whites (referent).





HR 95% CI P  HR 95% CI P † HR 95% CI P ‡
Median OS, months
Black 12.2 16.6 1.84 1.10 to 3.08 .027 22.1 0.43 0.23 to 0.80 .005 0.72 0.38 to 1.38 .36
White 15.2 19.1 1.46 1.25 to 1.70  .0001 16.8 0.90 0.76 to 1.05 .29 1.31 1.12 to 1.53 .004
Median TTP, months
Black 5.5 11.0 2.56 1.54 to 4.25 .0007 7.3 0.70 0.39 to 1.24 .09 1.66 0.90 to 3.08 .32
White 6.8 9.2 1.44 1.52 to 1.67  .0001 6.9 0.97 0.83 to 1.14 .85 1.41 1.22 to 1.63  .0001
RR, %
Black 28.2 28.6 NA NA .97 28.0 0.93 0.28 to 3.10 .99 0.88 0.28 to 2.7 .96
White 32.8 48.0 0.52 0.40 to 0.69 .0001 37.5 1.24 0.91 to 1.70 .20 0.65 0.49 to 0.86 .002
Abbreviations: RR, response rate; TTP, time to progression; OS, overall survival; HR, hazard ratio; OR, odds ratio; IFL, irinotecan, fluorouracil, and leucovorin; FOLFOX,
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precludes conclusions about whether these differences explain the
associations of drug toxicity and tumor response with race.
Despite the increasing gap between black and white Americans
with regard to incidence and survival from CRC,3,4 this and other
investigations controlling for imbalances in stage at presentation and
treatment received have found similar treatment efficacy in white and
black CRC patients. In three subgroup analyses of patients treated with
adjuvant CRC therapy, black patients had similar disease-free survival
and OS as white patients; small absolute differences in OS were largely
attributable to non-CRC causes.19-21 In a study of care at Veterans’
Administration hospitals where access is essentially equal between
blacks and whites22 and in studies using population-based databases
able to adjust for stage at presentation, socioeconomics, and treatment
received, the black-white survival disparity is markedly reduced.2,5
Together with our findings of minimal racial differences in survival
and no differences in TTP in metastatic CRC when treatment is
uniform, these studies suggest that any inherent racial differences in
CRC are, at most, a small contributing factor to CRC prognosis.
We did note a number of differences between black and white
patients that warrant further consideration. First, we found that
black patients are less likely to achieve an objective response than
white patients, which is a potentially important difference because
lower RRs might translate to a lower rate of resection with curative
intent. RR is clearly a marker for an increased chance of metastectomy.
In N9741, FOLFOX was associated with a higher RR (45%) compared
with IFL (31%) and IROX (35%),16 and oxaliplatin-treated patients
were more likely to undergo metastectomy than those treated with
IFL.23 In our analysis, there was no difference in metasectomy rate
by race; however, this trial was conducted at a time when the
potential benefits of resection of metastatic disease was just begin-
ning to be understood.
One supposition for the lower RR in blacks is the increased
proportion of lower grade tumors, which may grow more slowly and
be less likely to respond to treatment—analogous to the differences
between low-grade and intermediate-grade lymphomas. Another
possible explanation for the lower RR among black patients is the
higher proportion of black patients who received prior adjuvant ther-
apy (21% of black patients v 14% of white patients). In an analysis of
prognostic factors of cancer outcomes from this same trial, we found
that patients receiving prior adjuvant therapy had a lower objective RR
(33%) than previously untreated patients (39%; OR  0.64; 95% CI,
0.47 to 0.87).24 Adjusting for prior adjuvant therapy, however, did not
change the likelihood of response in multivariate models. Addition-
ally, although RR was significantly lower for black patients treated with
all regimens, TTP differed minimally between the groups, suggesting
that RR may be a poor surrogate for treatment efficacy in this cohort.
However, the lower RR in blacks might occur because of
pharmacogenetic differences resulting in blacks having lower drug
exposure despite equal dose-intensity. We did find a clinically and
statistically significant difference in the rate of severe AEs between
blacks and whites; this difference was largely attributable to an abso-
lute 12% higher rate of severe diarrhea in white patients. In a similar
subgroup analysis of the adjuvant trial INT 0089, black patients were
also less likely than white patients to have severe diarrhea (8% v 23%,
respectively; P  .001),19 supporting a true differential risk of severe
diarrhea from both combination chemotherapy and FU/LV. Al-
though we cannot be certain that AE reporting was performed equally
in blacks and whites—there may be societal differences in willingness
to report certain AEs—we have no reason to believe that this differ-
ence is solely the result of an ascertainment bias. Rather, it likely
represents differences in the frequency of currently unrecognized ge-
netic variants that regulate risk of diarrhea from chemotherapy.
By interaction testing, we found that, compared with both IFL
and FOLFOX, the OS benefit of IROX depended on patient race.
Specifically, IROX provided a significant improvement compared
with IFL and a trend toward benefit over FOLFOX in black patients.
This is primarily a result of the high 22.1-month median survival time
of black patients on the IROX arm, which is based on only 26 patients.
Coupled with no improvement on the TTP and RR end points for
Table 4. AEs by Treatment Arm and Race













No. % No. % No. % No. % No. % No. %
Overall
Black 116 76 66 40 34† 10 9 6 5 11 9 7 6
White 1,296 1,021 79 618 48 107 8 219 17 108 8 58 4
IFL
Black 39 22 56‡ 11 28‡ 4 10 3 8‡ 1 3 1 3
White 371 273 74 167 45 20 5 85 23 6 2 11 3
FOLFOX
Black 50 36 72§ 18 36 4 8 1 2§ 8 16 2 4
White 590 486 82 269 46 72 12 59 10 81 14 14 2
IROX
Black 27 18 67 11 41 2 7 2 7§ 2 7 4 15
White 335 262 78 182 54 15 4 75 22 21 6 33 10




§P  .05 to .1.
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IROX in black patients, this observed association may be a conse-
quence of the small sample size, rather than a biologic effect, and
requires confirmation in other clinical trials.
We found that the frequencies of many allelic variants of impor-
tance to irinotecan, oxaliplatin, and FU differ between blacks and
whites. This is not surprising because dramatic differences in genetic
variants have been described from both the Human Genome Project
and HapMap initiatives.12,25,26 However, the clinical relevance of these
racial differences is unclear. The UGT1A1 7/7 genotype is associated
with a higher risk of severe neutropenia,18 yet the greater frequency of
the 7/7 genotype in black patients did not result in a heightened risk of
this toxicity. Similarly, the distribution of GSTM1*0, which was asso-
ciated with decreased likelihood of severe neutropenia in FOLFOX-
treated patients in a pharmacogenetic analysis of N9741,27 was
inconsistent with the clinical findings of our subgroup analysis; black
patients were much more likely to have the low-risk GSTM1*0 (94%
in blacks v 49% in whites), but there was no difference in the incidence
of severe neutropenia events. On the basis of this preliminary data, a
single genotypic difference is unlikely to account for the observed
racial variation in AEs and RR; rather, if these differences are geneti-
cally determined, they are likely mediated by a complex interplay
of genotypes.
If confirmed, the lower rates of AEs experienced by black patients
in this study might allow for dose-escalation trials to overcome the
lower RR noted among black patients. There are data to suggest a
dose-response effect for single-agent irinotecan, data that are of par-
ticular interest given the poor survival of black patients treated with
IFL in N9741. Escalation of single-agent irinotecan from a dose of 250
mg/m2 to 500 mg/m2 was possible in some patients treated in a













G/G 35 97 442 98
A/G 0 0 4 1
Missing 1 3 4 1
DPYD5 .45
A/A 25 69 285 63
A/G and G/G 9 26 139 31
Missing 2 6 26 6
DPYD9A  .0001
A/A 8 22 267 59
A/G and G/G 28 78 180 40




G/G and T/T 2 6 98 22
T/G, T/T, C/T, C/C 34 94 352 78
Missing 0 0 0 0
TYMS 1494del .011
Other 26 72 224 50
A/A 10 28 223 49
Missing 0 0 3 1
TYMS TSER .56
2/2 or 2/3 25 69 303 67
3/3 9 25 138 31
Missing 2 6 9 2
Irinotecan genes
ABCB1 3435CT  .0001
Other 17 47 364 81
C/C 18 50 78 17
Missing 1 3 8 2
CYP3A4 1B and 3  .0001
A/G, G/G, T/C 32 89 33 7
A/A or T/T 4 11 414 92
Missing 0 0 3 1
CYP3A53  .0001
C/T and T/T 31 86 48 10
C/C 5 14 401 89
Missing 0 0 1 1
UGT1A128 .0081
6/6 4 11 206 45
6/7 15 42 196 44
7/7 5 14 39 9
Missing 12 33 9 2
ABCC23 .051
Other 21 58 161 36
A/A 1 3 46 10
Missing 14 39 423 54
Oxaliplatin genes
ERCC1 N118N  .0001
Other 10 28 372 83
C/C 22 61 57 13
Missing 4 11 21 4
ERCC2 K751Q .32
Other 32 89 383 85
G/G 3 8 66 14
Missing 1 3 1 1
(continued in next column)











ERCC2 D711D haplotype .0002
A/A 1 3 71 16
A/B 7 20 162 36
B/B 16 44 89 20
Missing 12 33 128 28
GSTP1 I105V .069
T/T 9 25 192 43
C/T 18 50 196 44
C/C 7 19 47 10
Missing 2 6 15 3
GSTM1 deletion  .0001
Absent 1 3 228 51
Present 34 94 222 49
Missing 1 3 0 0
XRCC1 R399Q .0006
Other 10 28 255 57
C/C 25 69 182 40
Missing 1 3 13 3
ABCG2 Q141K .017
G/T or T/T 1 3 90 20
G/G 29 80 327 73
Missing 6 17 33 7
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randomized phase II trial of standard versus escalating or individual-
ized dosing based on prognostic determinants.28 This study showed a
trend toward higher RR in patients who were able to undergo dose
escalation, although in this small trial, dose escalation prolonged nei-
ther TTP nor OS.
A more promising strategy than race-based dose escalation,
however, is the ascertainment of objective predictors of treatment
response, such as genotype. We found marked racial differences in
frequency of polymorphisms of important CRC chemotherapy-
related genes. Although no one gene emerged as a clear causal candi-
date, future studies with adequate sample size to model the three-way
association between toxicity, race, and genotype will hopefully identify
a complex of genes that may underlie the racial discrepancy in re-
sponse and severe diarrhea. This strategy may have broad applicability
across races, ethnicities, and disease processes and, in time, deliver on
the promise of genotype-guided treatment approaches.
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